CD14 and glioblastoma: In a trial testing DCs for patients with primary recurrent glioblastoma, both CD15+SSClo cells and CD14+HLA-DRlo/neg monocytes were found to be elevated in patients that progressed but only the CD14+HLA-DRlo/neg monocytes were found to be both higher as a percent of parent populations and also in cell counts (cells/μl) (72).